This entry covers evaluation under DC 7345. A clinician establishes the diagnosis separately.
How is it connected to service?
The applicable direct, secondary, aggravation or presumptive route determines the service-connection evidence. Use the evidence guide to distinguish these routes.
Explore service-connection evidence →What do the rating levels describe?
A diagnosis does not automatically establish a percentage. These are the source requirements for evaluating severity; related notes and exceptions still apply.
Compare these levels with the original rating table
Find DC 7345 in the rating schedule
The highlighted row marks this code. Nearby rows provide context and can describe other conditions. Use the full schedule for applicable headings, footnotes and exceptions.
| Rating | |
|---|---|
| Evaluate under a diagnostic code appropriate to the predominant disability or the specific residuals after treatment. | |
| Note: This diagnostic code includes lipoma, leiomyoma, colon polyps, or villous adenoma. | |
| 7345 Chronic liver disease without cirrhosis: | |
| Progressive chronic liver disease requiring use of both parenteral antiviral therapy (direct antiviral agents), and parenteral immunomodulatory therapy (interferon and other); and for six months following discontinuance of treatment | 100 |
| Progressive chronic liver disease requiring continuous medication and causing substantial weight loss and at least two of the following: (1) daily fatigue, (2) malaise, (3) anorexia, (4) hepatomegaly, (5) pruritus, and (6) arthralgia | 60 |
| Progressive chronic liver disease requiring continuous medication and causing minor weight loss and at least two of the following: (1) daily fatigue, (2) malaise, (3) anorexia, (4) hepatomegaly, (5) pruritus, and (6) arthralgia | 40 |
| Chronic liver disease with at least one of the following: (1) intermittent fatigue, (2) malaise, (3) anorexia, (4) hepatomegaly, or (5) pruritus | 20 |
| Previous history of liver disease, currently asymptomatic | 0 |
| Note (1): 100% evaluation shall continue for six months following discontinuance of parenteral antiviral therapy and administration of parenteral immunomodulatory drugs. Six months after discontinuance of parenteral antiviral therapy and parenteral immunomodulatory drugs, determine the appropriate disability rating by mandatory VA exam. Apply the provisions of § 3.105(e) of this chapter to any change in evaluation based upon that or any subsequent examination. |
Related notes and evaluation rules
Note (1): 100% evaluation shall continue for six months following discontinuance of parenteral antiviral therapy and administration of parenteral immunomodulatory drugs. Six months after discontinuance of parenteral antiviral therapy and parenteral immunomodulatory drugs, determine the appropriate disability rating by mandatory VA exam. Apply the provisions of § 3.105(e) of this chapter to any change in evaluation based upon that or any subsequent examination.
Note (2): For individuals for whom physicians recommend both parenteral antiviral therapy and parenteral immunomodulatory drugs, but for whom treatment is medically contraindicated, rate according to DC 7312 (Cirrhosis of the liver).
Note (3): This diagnostic code includes Hepatitis B (confirmed by serologic testing), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), autoimmune liver disease, Wilson's disease, Alpha-1-antitrypsin deficiency, hemochromatosis, drug-induced hepatitis, and non-alcoholic steatohepatitis (NASH). Track Hepatitis C (or non-A, non-B hepatitis) under DC 7354 but evaluate it using the criteria in this entry.
Note (4): Evaluate sequelae, such as cirrhosis or malignancy of the liver, under an appropriate diagnostic code, but do not use the same signs and symptoms as the basis for evaluation under DC 7354 and under a diagnostic code for sequelae. (See § 4.14)
Note (2): For individuals for whom physicians recommend both parenteral antiviral therapy and parenteral immunomodulatory drugs, but for whom treatment is medically contraindicated, rate according to DC 7312 (Cirrhosis of the liver). |
Note (3): This diagnostic code includes Hepatitis B (confirmed by serologic testing), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), autoimmune liver disease, Wilson's disease, Alpha-1-antitrypsin deficiency, hemochromatosis, drug-induced hepatitis, and non-alcoholic steatohepatitis (NASH). Track Hepatitis C (or non-A, non-B hepatitis) under DC 7354 but evaluate it using the criteria in this entry. |
Note (4): Evaluate sequelae, such as cirrhosis or malignancy of the liver, under an appropriate diagnostic code, but do not use the same signs and symptoms as the basis for evaluation under DC 7354 and under a diagnostic code for sequelae. (See § 4.14) |
Which evidence addresses the questions?
- Diagnosis and history: Records identifying the current diagnosis, onset, course, and relevant medical history.
- Diagnostic tests and measurements: Condition-relevant tests, imaging, laboratory results, and objective measurements.
- Symptoms and episodes: Records or statements documenting symptoms, severity, frequency, duration, and episodes.
- Treatment and medications: Treatment records, medication history, procedures, and therapy documentation.
- Clinical findings: Examination findings that are relevant to the public DBQ or rating criteria.
- Scars and residual findings: Records describing relevant scars and residual physical findings.
- Functional impact: Medical and lay evidence describing work and daily-activity effects.
- Service connection evidence: Evidence addressing an in-service event, exposure, disease, injury, continuity, or a secondary relationship.
Find evidence in the Liver Conditions questionnaire
Use these section names and page numbers to locate the examiner’s findings. Some sections apply only to particular diagnoses within this family.
- diagnosis · p. 1, 2
- medical history · p. 2
- chronic liver disease without cirrhosis (including hepatitis) · p. 3, 4
- cirrhosis of the liver · p. 4, 5
- liver abscess · p. 5
- liver transplant · p. 5
- diagnostic testing · p. 6, 7
- tumors and neoplasms · p. 7, 8
- other pertinent physical findings, complications, conditions, signs, symptoms, and scars · p. 8
- functional impact · p. 8
- remarks · p. 9
Shared library and examination references
How an independent medical review works →Sources and scope
Clinical and evidence sources
Guide source check: 2026-11-06. Rating-library snapshot: June 30, 2026. Source coverage is distinct from clinical review. This page does not diagnose, adjudicate a claim, or collect medical records.
Shared reference edition 1.2.4 · source check 2026-11-06. Coverage is stated for each framework and is distinct from clinical review. Rating-source snapshot: 2026-06-30.